Amgen reported strong second-quarter performance with a 14% revenue increase and a 19% rise in adjusted EPS, along with raised guidance. The successful execution of cost-saving measures and significant share repurchases further support a positive short-term outlook despite minor concerns over clinical trial delays.

[1]